August 9, 2021 Another class action alleges Takeda and Par have conspired to suppress competition in the generic drug market, this time for Colcrys (colchicine).
June 13, 2019 Two healthcare plans have joined the ranks of those suing Big Pharma heavyweights over their alleged contributions to the national opioid crisis that has devastated the nation.
February 22, 2019 Amgen Inc., Teva Pharmaceuticals USA, Inc. and three Teva subsidiaries have been named in a proposed class action in which they’re accused of entering into an unlawful, anticompetitive agreement that led consumers to pay inflated prices for Sensipar.
April 26, 2018 Another proposed class action filed on behalf of children born with Neonatal Abstinence Syndrome accuses a group of pharmaceutical companies and distributors of contributing to the 'opioid epidemic' that has swept across the state of Louisiana.
March 30, 2018 Another proposed class action filed on behalf of a minor child diagnosed with NAS has been added to the multidistrict litigation involving pharmaceutical companies’ and distributors’ alleged contributions to the country’s growing 'opioid epidemic.'
March 9, 2018 A growing number of lawsuits have been filed against a group of pharmaceutical companies and distributors over claims that the defendants have caused a national health crisis by deceptively marketing opioids for long-term use.
March 7, 2018 Another proposed class action has been filed against a group of 22 pharmaceutical companies and distributors over claims that the defendants’ deceptive marketing scheme and negligence have fueled the nation’s growing opioid crisis.
March 6, 2018 A group of 20 pharmaceutical companies and distributors has been named in a proposed class action lawsuit filed on behalf of a newborn baby who the suit claims suffers from neonatal abstinence syndrome (NAS) as a result of the defendants’ actions.
January 19, 2018 A group of pharmaceutical companies is facing a proposed class action lawsuit that claims the defendants, since the 1990s, have misled doctors and patients regarding the risks associated with using opioids to treat chronic pain.
December 5, 2017 Three Mississippi hospitals claim the conduct of 19 pharma-industry heavyweights contributed greatly to the nation's opioid abuse epidemic.
November 16, 2017 Another proposed class action has been filed against various pharmaceutical companies and distributors, claiming the defendants’ deceptive marketing of opioid products has contributed to their widespread abuse.
November 16, 2017 A proposed class action has been filed against a group of pharmaceutical companies and distributors over claims that they deceptively marketed and sold opioids without fully disclosing their associated risks.
